Irbepress-Hct

Hydrochlorothiazide and Irbesartan, the active ingredients in Irbepress-Hct, are an angiotensin II receptor blocker and thiazide diuretic combination presented as an oral tablet for oral use. It treats hypertension in adults.

GNH USA supplies Irbepress-Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbepress-Hct is used to manage high blood pressure, a key component of the renin‑angiotensin‑aldosterone system pathway.

- Hypertension: lowers systolic and diastolic pressure, reducing the risk of cardiovascular events.

Irbepress-Hct may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia, especially when combined with potassium‑sparing agents - Angioedema or severe allergic reaction - Significant hypotension - Pancreatitis (rare)

Before prescribing Irbepress-Hct, clinicians should consider several safety factors.

- Renal function: monitor serum creatinine and eGFR regularly. - Electrolytes: check potassium and sodium levels, especially in the first weeks. - Concomitant diuretics: adjust dose to avoid excessive volume depletion. - Pregnancy: use only if the potential benefit justifies the potential risk, as safety data are limited. - Sulfonamide allergy: avoid in patients with known hypersensitivity to sulfonamide structures. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbepress-Hct can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren combined with an ARB in diabetic patients: risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels and toxicity. - ACE inhibitors or other ARBs: additive effects on blood pressure and potassium. - NSAIDs: may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustments to prevent hypotension. - CYP2C9 inhibitors (e.g., fluconazole): can increase irbesartan plasma concentrations. - Antidiabetic agents: monitor blood glucose as blood pressure changes can affect glycemic control.